1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
(650) 781-5200
https://www.kronosbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 61
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
La calificación ISS Governance QuickScore de Kronos Bio, Inc. a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 8; Compensación: 8.